EyeGene,Inc Logo

EyeGene,Inc

Develops gene/cell therapies & mRNA vaccines for age-related and ocular diseases.

185490 | KO

Overview

Corporate Details

ISIN(s):
KR7185490000
LEI:
Country:
South Korea
Address:
경기도 의왕시 양지편2로 13 2층, 의왕시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

EyeGene, Inc. is a clinical-stage biotechnology company focused on the research and development of innovative biopharmaceuticals. The company is pioneering gene and cell therapies to create transformative treatments for various conditions, with a historical focus on age-related and ocular diseases. Leveraging advanced technologies such as mRNA platforms and immunology, EyeGene develops a pipeline of novel therapeutics and vaccines. The company aims to become a global biopharmaceutical leader by advancing treatment and prevention through data-driven research to address unmet medical needs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-17 00:00
Registration Form
증권신고서(지분증권) (2025.11)
Korean 1.8 MB
2025-09-16 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 32.6 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-06-30 00:00
Regulatory News Service
투자판단관련주요경영사항(임상시험계획승인신청등결정) (4가 수막구균 접합백신 ‘EGMCV4의 국내 임상 제2/3상 임상시…
Korean 17.9 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.1 MB
2025-05-12 00:00
Share Issue/Capital Change
주식매수선택권부여에관한신고
Korean 18.1 KB
2025-03-26 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 21.4 KB
2025-03-18 00:00
Audit Report / Information
감사보고서제출
Korean 26.5 KB
2025-03-18 00:00
Annual Report
사업보고서 (2024.12)
Korean 1.7 MB
2025-03-11 00:00
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
Korean 158.3 KB
2025-03-10 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 159.1 KB
2025-03-04 00:00
Regulatory News Service
투자판단관련주요경영사항(임상시험계획승인신청) (EGMCV4수막구균(혈청형 A, C, W135 및 Y군) 접합백신의 면역…
Korean 12.1 KB
2025-02-28 00:00
Legal Proceedings Report
투자판단관련주요경영사항(임상시험결과) (아이진 mRNA 기반 코로나19 예방백신 (EGCOVID) ‘이지코비드(EGC…
Korean 14.5 KB
2025-02-28 00:00
Regulatory News Service
투자판단관련주요경영사항(임상시험결과) (mRNA 기반 코로나19 예방 다가백신 이지코브투(EGCOVII) 호주 임상 제…
Korean 14.9 KB
2025-02-26 00:00
Legal Proceedings Report
투자판단관련주요경영사항(임상시험계획자진취하등) (4가 수막구균 접합백신 ‘EGMCV4의 국내 임상 3상 임상시험계획(I…
Korean 11.1 KB

Automate Your Workflow. Get a real-time feed of all EyeGene,Inc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for EyeGene,Inc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for EyeGene,Inc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Bioengineering solutions to accelerate life sciences research, from gene synthesis to cell lines.
South Korea
355690
aTYR PHARMA INC Logo
Developing novel medicines for fibrosis and inflammation using tRNA synthetase biology.
United States of America
ATYR
Aura Biosciences, Inc. Logo
Developing virus-like therapies to selectively destroy solid tumors in ocular & urologic oncology.
United States of America
AURA
Aurinia Pharmaceuticals Inc. Logo
Biopharma developing therapies for autoimmune and kidney diseases like lupus nephritis.
United States of America
AUPH
AURORA CANNABIS INC Logo
A global producer and seller of medical and recreational cannabis and derivative products.
United States of America
ACB
Autolus Therapeutics plc Logo
Develops programmed CAR T-cell therapies for cancer and autoimmune diseases.
United States of America
AUTL
AVADEL PHARMACEUTICALS PLC Logo
Develops once-at-bedtime therapies for adults with narcolepsy using innovative drug delivery.
United States of America
AVDL
Avidity Biosciences, Inc. Logo
Pioneering targeted RNA therapies that treat the root cause of rare muscle diseases.
United States of America
RNA
Axsome Therapeutics, Inc. Logo
Biopharma company developing novel therapies for central nervous system (CNS) conditions.
United States of America
AXSM
AYTU BIOPHARMA, INC Logo
Specialty pharma advancing innovative medicines for CNS diseases like MDD and ADHD.
United States of America
AYTU

Talk to a Data Expert

Have a question? We'll get back to you promptly.